Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH. |  |
|
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Silverstein Christine Berni | Director | Jul 09 '25 | Sale | 5.86 | 13,093 | 76,669 | 120,479 | Jul 10 04:30 PM | | Seshadri Vishwas | Chief Executive Officer | Jul 09 '25 | Sale | 5.86 | 69,420 | 406,503 | 1,234,341 | Jul 10 04:30 PM | | Vazzano Joseph Walter | Chief Financial Officer | Jul 09 '25 | Sale | 5.86 | 25,411 | 148,799 | 479,168 | Jul 10 04:30 PM | | Wuchterl Donald A. | Director | Jul 08 '25 | Sale | 5.82 | 5,176 | 30,147 | 145,436 | Jul 10 04:30 PM | | Charles Faith L. | Director | Jul 09 '25 | Sale | 5.86 | 10,738 | 62,879 | 139,094 | Jul 10 04:30 PM | | O'Malley Brendan M. | SVP, Chief Legal Officer | Jul 09 '25 | Sale | 5.86 | 17,428 | 102,053 | 360,817 | Jul 10 04:30 PM | | Alvino Mark | Director | Jul 09 '25 | Sale | 5.86 | 13,093 | 76,669 | 77,252 | Jul 10 04:30 PM | | Vazzano Joseph Walter | Officer | Jul 09 '25 | Proposed Sale | 5.86 | 25,335 | 148,354 | | Jul 09 04:55 PM | | Seshadri Vishwas | Officer | Jul 09 '25 | Proposed Sale | 5.86 | 69,215 | 405,302 | | Jul 09 04:52 PM | | O'Malley Brendan M. | Officer | Jul 09 '25 | Proposed Sale | 5.86 | 17,376 | 101,749 | | Jul 09 04:48 PM | | Charles Faith L. | Director | Jul 09 '25 | Proposed Sale | 5.86 | 10,706 | 62,691 | | Jul 09 04:45 PM | | Silverstein Christine Berni | Director | Jul 09 '25 | Proposed Sale | 5.86 | 13,054 | 76,440 | | Jul 09 04:40 PM | | Alvino Mark | Director | Jul 09 '25 | Proposed Sale | 5.86 | 13,054 | 76,440 | | Jul 09 04:36 PM | | Wuchterl Donald A. | Director | Jul 08 '25 | Proposed Sale | 5.82 | 5,176 | 30,147 | | Jul 08 04:06 PM | | Vazzano Joseph Walter | Chief Financial Officer | Jun 06 '25 | Sale | 6.76 | 17,795 | 120,294 | 491,246 | Jun 06 06:04 PM | | Seshadri Vishwas | Chief Executive Officer | Jun 06 '25 | Sale | 6.76 | 50,676 | 342,570 | 1,303,761 | Jun 06 06:00 PM | | O'Malley Brendan M. | SVP, General Counsel | Jun 06 '25 | Sale | 6.76 | 10,470 | 70,777 | 378,245 | Jun 06 05:56 PM | | Vazzano Joseph Walter | Officer | Jun 06 '25 | Proposed Sale | 6.76 | 17,795 | 120,314 | | Jun 06 04:13 PM | | O'Malley Brendan M. | Director | Jun 06 '25 | Proposed Sale | 6.76 | 10,470 | 70,789 | | Jun 06 04:12 PM | | Seshadri Vishwas | Officer | Jun 06 '25 | Proposed Sale | 6.76 | 50,676 | 342,626 | | Jun 06 04:11 PM | | Alvino Mark | Director | May 27 '25 | Sale | 6.38 | 2,000 | 12,760 | 90,435 | May 27 07:57 PM | | Alvino Mark | Director | May 27 '25 | Proposed Sale | 6.38 | 2,000 | 12,762 | | May 27 04:40 PM | | Alvino Mark | Director | May 16 '25 | Sale | 5.68 | 8,000 | 45,440 | 92,435 | May 16 05:23 PM | | Alvino Mark | Director | May 16 '25 | Proposed Sale | 5.68 | 8,000 | 45,423 | | May 16 04:07 PM | | Seshadri Vishwas | Chief Executive Officer | Mar 31 '25 | Sale | 4.78 | 25,000 | 119,500 | 1,355,322 | Mar 31 07:17 PM | | Seshadri Vishwas | Officer | Mar 31 '25 | Proposed Sale | 4.78 | 25,000 | 119,560 | | Mar 31 04:08 PM | | Alvino Mark | Director | Jan 29 '25 | Sale | 5.38 | 4,000 | 21,520 | 64,334 | Jan 31 04:30 PM | | Alvino Mark | Officer | Jan 29 '25 | Proposed Sale | 5.41 | 4,000 | 21,640 | | Jan 29 04:03 PM | | Alvino Mark | Director | Jan 21 '25 | Sale | 5.10 | 4,000 | 20,400 | 68,334 | Jan 21 04:30 PM | | Alvino Mark | Officer | Jan 21 '25 | Proposed Sale | 5.22 | 4,000 | 20,880 | | Jan 21 04:05 PM |
|
